Russell Investments Group Ltd. raised its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 40.6% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 86,239 shares of the biotechnology company’s stock after buying an additional 24,884 shares during the period. Russell Investments Group Ltd. owned about 0.20% of United Therapeutics worth $45,617,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of UTHR. BlackRock Inc. bought a new stake in shares of United Therapeutics during the second quarter worth $2,868,735,000. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the period. Jupiter Topco LLC bought a new position in United Therapeutics in the second quarter valued at about $450,140,000. First Trust Advisors LP boosted its holdings in United Therapeutics by 23.5% in the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after acquiring an additional 51,555 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in United Therapeutics in the second quarter valued at about $159,522,000. 94.08% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
UTHR has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $850.00 price objective on shares of United Therapeutics in a research report on Monday, October 26th. HC Wainwright began coverage on shares of United Therapeutics in a research report on Monday, November 9th. They set a “buy” rating and a $660.00 target price on the stock. Morgan Stanley raised their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. BTIG Research raised their target price on shares of United Therapeutics from $728.00 to $768.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Finally, Leerink Partners lifted their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $676.40.
Read Our Latest Report on UTHR
Insider Activity at United Therapeutics
In related news, Director Christopher Patusky sold 1,210 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $580.00, for a total transaction of $701,800.00. Following the completion of the transaction, the director owned 2,140 shares in the company, valued at approximately $1,241,200. The trade was a 36.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $27,043,121.24. This represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 402,738 shares of company stock worth $216,162,401. 8.60% of the stock is owned by insiders.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $591.17 on Monday. The firm has a fifty day moving average of $542.60 and a two-hundred day moving average of $536.37. The stock has a market capitalization of $25.18 billion, a price-to-earnings ratio of 22.31, a PEG ratio of 3.93 and a beta of 0.49. United Therapeutics Corporation has a 52 week low of $455.63 and a 52 week high of $614.23.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the prior year, the business earned $7.16 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 25.08 EPS for the current fiscal year.
United Therapeutics announced that its Board of Directors has approved a stock buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Stories
- Five stocks we like better than United Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
